 |
|
|
| |
Long-term Entecavir Therapy Results in Reversal of Fibrosis/Cirrhosis and Continued Histologic Improvement in Patients with HBeAg(+) and (-) Chronic Hepatitis B:
Results from Studies ETV-022, -027 and -901
|
| |
| |
Reported by Jules Levin
13th ISVHLD Wash Dc March 20-24 2009
Y-F Liaw1, T-T Chang2, S-S Wu3, ER Schiff4, K-H Han5, C-L Lai6, R Safadi7,
SS Lee8, W Halota9, ZD Goodman10, H Zhang11, R Hindes11, U Iloeje11, S Beebe11 and B Kreter12
1. Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei, Taiwan; 2. National Cheng Kung University Medical College, Tainan,
Taiwan; 3. Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan; 4. University of Miami Hospital & Clinics, Miami, FL, USA;
5. Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea; 6. Department of Medicine, Queen Mary's Hospital, University of Hong Kong, Hong Kong, China; 7. Division of Medicine, Hadassah Medical Center, Jerusalem, Israel; 8. Liver Unit, University of Calgary, Calgary, AB, Canada; 9. Klinika Chorob Zakaznych AM, Bydgoszcz, Poland; 10. Armed Forces Institute of Pathology, Washington, WA, USA; 11. Research & Development, Bristol-Myers Squibb Company, Wallingford, CT, USA; 12. Research & Development, Bristol-Myers Squibb Company, Princeton, NJ, USA
|
| |
|
|
|
|
|
